Does TRT Shorten Your Life? What the Research Says
Separating fear from evidence on testosterone therapy and longevity.
10 min read
“Will TRT shorten my life?” It's one of the most common fears men have before starting testosterone replacement therapy — and one of the most misunderstood topics in men's health. Headlines over the past decade have swung wildly between “testosterone causes heart attacks” and “TRT may actually extend your life.”
The reality is more nuanced than either extreme. This guide walks through the major studies, what they actually found, and what the current medical consensus looks like — so you can have an informed conversation with your provider instead of making decisions based on fear.
The Short Answer
The current weight of evidence does not support the claim that properly monitored TRT shortens your life. In fact, several large studies suggest that treating low testosterone in men who have clinical symptoms may improve cardiovascular outcomes and reduce all-cause mortality compared to leaving low testosterone untreated. However, TRT is not risk-free, and outcomes depend heavily on proper dosing, monitoring, and patient selection.
This is an overview of published research, not medical advice. Discuss your individual risk factors with your healthcare provider.
Where the Fear Came From
The concern about TRT and mortality traces back to a few high-profile studies and FDA actions that generated alarming headlines. Understanding the context behind them matters:
The TOM Trial (Testosterone in Older Men with Mobility Limitations)
Finding: This small trial was stopped early after a higher rate of cardiovascular events was observed in the testosterone group compared to placebo among frail elderly men (average age 74) with significant pre-existing health conditions.
Context: The study population was older and sicker than typical TRT candidates. The testosterone doses used were high, producing supraphysiological levels in many participants. Most TRT clinics today would not treat this population with these protocols.
Vigen et al. (JAMA)
Finding: A retrospective study of VA patients reported higher cardiovascular event rates among men prescribed testosterone. This study generated massive media coverage and contributed to the FDA's safety review.
Context: This study was heavily criticized by the medical community. It contained statistical errors (later corrected), included women in the analysis by mistake, and the "testosterone group" had worse baseline health. Multiple subsequent analyses of the same data did not replicate the findings.
FDA Safety Communication
Finding: The FDA added a warning to testosterone products about possible increased cardiovascular risk and required manufacturers to conduct long-term safety studies.
Context: The FDA's action was precautionary, not a conclusion that TRT causes harm. It reflected uncertainty in the data at the time and a desire for more rigorous evidence — which has since been produced.
Finkle et al. (PLOS ONE)
Finding: An insurance claims analysis reported a higher rate of heart attacks in men in the 90 days after filling a testosterone prescription.
Context: Claims-based studies cannot determine whether patients actually used the medication or were being treated appropriately. Men who seek TRT often have pre-existing metabolic risk factors that independently increase cardiovascular risk.
What Newer Research Shows
Since the initial wave of concern, larger and better-designed studies have provided a more complete picture. The overall trend has been reassuring:
Sharma et al. (European Heart Journal)
A large observational study of over 83,000 male veterans with low testosterone found that men whose levels normalized on TRT had significantly lower all-cause mortality and reduced rates of heart attack and stroke compared to men whose levels remained low.
Cheetham et al. (JAMA Internal Medicine)
A retrospective cohort study of over 15,000 men found no increased cardiovascular risk from testosterone therapy. Men on TRT had similar cardiovascular event rates to untreated men with normal testosterone.
The TRAVERSE Trial (New England Journal of Medicine)
The largest and most rigorous randomized controlled trial on TRT cardiovascular safety to date. Over 5,000 men aged 45–80 with pre-existing cardiovascular disease or high risk were randomized to testosterone gel or placebo for an average of 33 months. The result: TRT did not increase the rate of major cardiovascular events compared to placebo.
Lincoff et al. (Follow-up Analysis)
Extended analysis of TRAVERSE data confirmed no increase in mortality or major adverse cardiac events, and showed improvements in sexual function, physical activity, and bone density in the TRT group.
Why the TRAVERSE Trial Matters Most
The TRAVERSE trial is the study the FDA specifically asked for in 2014 when it required testosterone manufacturers to conduct long-term cardiovascular safety research. It's the gold standard for answering the “does TRT shorten your life” question because of its design:
Randomized & Placebo-Controlled
The strongest study design — eliminates selection bias
5,246 Participants
Large enough to detect meaningful differences in rare events
High-Risk Population
Enrolled men with or at high risk for heart disease — a harder test for safety
33 Months Average Follow-Up
Long enough to capture cardiovascular events that develop over time
Published in NEJM
Peer-reviewed in the highest-impact medical journal
FDA-Mandated
Designed specifically to answer the regulatory safety question
The bottom line from TRAVERSE: in a population specifically selected for high cardiovascular risk, TRT did not increase heart attacks, strokes, or death compared to placebo. This is the strongest evidence to date that properly prescribed TRT does not shorten your life.
Real Risks That Do Exist With TRT
Saying TRT doesn't shorten your life is not the same as saying it's risk-free. There are real side effects and risks that require monitoring:
Elevated Red Blood Cells (Polycythemia)
Monitor closelyTRT stimulates red blood cell production. If hematocrit rises too high (typically above 54%), it increases the risk of blood clots. This is the most common safety concern and the primary reason regular blood work is essential.
Fertility Suppression
MonitorTRT suppresses sperm production, sometimes to zero. This is not a longevity risk, but it's a major consideration for men who want children. HCG or other interventions can mitigate this.
Sleep Apnea Worsening
MonitorTRT may worsen existing obstructive sleep apnea in some men. Untreated sleep apnea is itself a cardiovascular risk factor, so this should be evaluated and managed.
Estrogen Elevation
ManageableTestosterone converts to estradiol via aromatization. Elevated estrogen can cause water retention, gynecomastia, and mood changes. Monitored via blood work and managed with dose adjustment or aromatase inhibitors when needed.
Prostate Considerations
MonitorTRT does not cause prostate cancer based on current evidence, but it can increase PSA levels. Men with active prostate cancer should not use TRT. Regular PSA monitoring is part of standard TRT oversight.
The Flip Side: Risks of Untreated Low Testosterone
The “does TRT shorten your life” question is incomplete without asking the inverse: what happens if you leave low testosterone untreated? The research on this is actually quite consistent:
- ⚠Multiple large studies associate low testosterone with increased all-cause mortality independent of other risk factors
- ⚠Low T is linked to higher rates of metabolic syndrome, type 2 diabetes, and obesity — all of which reduce lifespan
- ⚠Untreated hypogonadism is associated with increased cardiovascular disease risk
- ⚠Low testosterone correlates with higher rates of depression, cognitive decline, and reduced quality of life
- ⚠Men with low T who normalize their levels (whether naturally or through TRT) tend to have better long-term outcomes than those who remain deficient
This doesn't mean every man with slightly below-average testosterone needs TRT. But for men with clinically low levels and clear symptoms, the risks of doing nothing may be greater than the risks of treatment.
What This Means for Your Decision
The key takeaways from the current state of the research:
TRT does not appear to increase cardiovascular risk when properly prescribed and monitored
The TRAVERSE trial — the largest and most rigorous study — found no increased risk of heart attack, stroke, or death in a high-risk population.
Untreated low testosterone carries its own health risks
Leaving clinical hypogonadism untreated is associated with increased mortality, metabolic disease, and reduced quality of life.
Monitoring is not optional
Regular blood work (CBC, estradiol, PSA, lipids, metabolic panel) is what keeps TRT safe. The risks that do exist — primarily polycythemia — are caught and managed through routine labs.
Provider quality matters enormously
A clinic that prescribes TRT without proper baseline labs, ongoing monitoring, and dose optimization is the actual risk factor — not the testosterone itself.
Related Guides
Find a Clinic That Monitors Properly
The safety of TRT depends on the quality of your provider. Search verified clinics that prioritize ongoing monitoring and lab work.